Innealta Capital’s ImmuCell ICCC Stock Holding History

Innealta Capital’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$5	–	870
2024 Q2	$5	Buy	+1	New	+$5	﹤0.01%	1828

Other funds holding ICCC

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Innealta Capital's ICCC Position: Q3 2024 in Review

Innealta Capital sold out of ImmuCell (ICCC) in Q3 2024, closing a stake of 1 share — an estimated $5 sold.

Innealta Capital first reported a position in ICCC in Q2 2024 and held it in 1 quarter. The position peaked at $5 in Q2 2024. 22 funds tracked by Wall St. Rank hold ICCC as of Q3 2024.

Innealta Capital reported no remaining ImmuCell position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 1 ImmuCell share in Q3 2024, an estimated $5.
Innealta Capital first reported a position in ImmuCell in Q2 2024 and held it in 1 quarter.
Innealta Capital's ImmuCell position peaked at $5 in Q2 2024.
22 funds tracked by Wall St. Rank held ImmuCell as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.